Atlas Bio

Who owns Atlas Bio?

Atlas Bio is currently owned by First Momentum Ventures through First Momentum Ventures Fund II (2025 vintage), since 2024. Across its history, Atlas Bio has been through 2 private equity ownership periods, detailed in the timeline below.

Hand-verified · updated 2026-07-03

About Atlas Bio

Atlas Bio is a Basel-based biotechnology company that applies deep learning to pharmaceutical development, building an AI foundation model designed to predict where a drug takes effect and to match candidate medicines to the diseases they are most likely to treat. The company frames its work around a central failure in drug development, namely that a large share of otherwise safe candidates fail in Phase II trials because exhaustive testing across every possible condition is impractical, and it positions its model as a faster route to that predictive step. It sits in the emerging AI-driven, or techbio, segment of drug discovery, competing with a cohort of foundation-model startups that aim to model human biology in silico rather than through animal or cell proxies, under the tagline that it models humans better. As an early-stage venture, Atlas Bio remains a small, founder-led team rather than a commercial-scale operator, with its activity concentrated on model development ahead of a marketed product.

Ownership journey

Atlas Bio was founded in 2024 in Basel, Switzerland, by Simon Romanski, Sebastian Beyer and Dominik Hartl, around the premise that better computational models of human response can reduce late-stage clinical attrition. In 2024 the company raised early venture funding from First Momentum Ventures, a deep-tech investor that lists Atlas Bio in its portfolio and backed the business through First Momentum Ventures Fund II at the pre-seed stage. In 2025 LEA Partners joined the cap table, investing through its LEA Venturepartner venture vehicle. Both firms remain active minority venture backers rather than controlling owners, and no exit or secondary transaction has been recorded; Atlas Bio continues to be listed as a current portfolio company by its investors.

Under PE ownership

The 2024 pre-seed capital was directed at building the company's AI foundation model and assembling its founding technical team, consistent with its investors' focus on machine-learning applications in healthcare and biotech. Since the initial backing, Atlas Bio has broadened its investor base, adding LEA Partners in 2025 to the support it first secured from First Momentum Ventures, extending its runway from a single pre-seed backer to a syndicate of European venture funds. The stated purpose of the model has sharpened around predicting a drug's area of effect and matching compounds to diseases, the problem the founders set out to address. As an early-stage company, its progress to date is measured in model development and investor support rather than revenue or headcount at scale, with no marketed product yet disclosed.